An official website of the United States government
Home
Name
Opdualag
Alternate Names
Nivolumab-relatlimab-rmbw
Opdivo/relatlimab-rmbw
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Monoclonal antibody
NSC Number
None
Primary Site
None
Histology
Melanoma
Remarks
March 18, 2022 The FDA approved nivolumab and relatlimab-rmbw (Opdualag) for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. Opdualag is a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the programmed death receptor-1 blocking antibody nivolumab. This drug is a fixed-dose combination of two monoclonal antibodies.
Coding
This drug should be coded
